Creative Bioarray Releases Comprehensive GPCR Assays to Accelerate GPCR Drug Discovery Research

DDA platform announced the release of its comprehensive GPCR screening services to accelerate drug discovery research.

New York, USA - January 19, 2021 /MarketersMedia/

DDA Platform, a division of Creative Bioarray, is an innovative biotechnology branch that focuses on providing global scientists with high quality products and services, aiming to facilitate the investigation of diverse researches in the field of biotechnology, pharmaceutical and diagnostics etc. Recently, DDA platform announced the release of its comprehensive GPCR screening services to accelerate drug discovery research.

GPCR mediates many important physiological functions and is considered to be one of the most successful therapeutic targets for a wide range of diseases. The design and application of high-throughput GPCR analysis is critical for early drug development, which can cost-effectively screen large compound libraries to identify new drug candidates. Early functional GPCR analysis mainly relied on the measurement of G protein-mediated second messengers. With the ever-increasing understanding of GPCR signal transduction, many G protein-independent pathways have been used to detect GPCR activity and may provide more information on the functional selectivity of candidate compounds. Creative Bioarray provides a comprehensive selection of combined and functional GPCR analysis to meet the needs of chemists and biologists for GPCR drug discovery research.

Creative Bioarray's GPCR detection service supports a variety of assay formats, and can provide customers with customized GPCR stable cell line generation. The professional team ensures high quality inspection standards, fast turnaround time, and ultimately provides accurate and repeatable results. A team with many years of customer service experience can provide services that customers need based on predefined GPCR panels or customized GPCR panels.

The ideal detection method for GPCR ligand screening should be simple, non-radioactive, robust, uniform, and easy to adapt to the automation of microtiter plate formats (96, 384 or 1536 wells). With more than 10 years of expertise in the biopharmaceutical field, Creative Bioarray provides hundreds of functional and radioligand binding GPCR analysis methods for high-throughput screening, molecular pharmacology and molecular profiling.

“Our global in vitro testing and screening scientists have expertise in various therapeutic areas, target types, assay formats, instruments and automation platforms, and are committed to helping you identify and develop the most promising compounds. We focus on standard and customized in vitro tests to provide customers with cost-effective, high-quality, reproducible data and flexible solutions.” said Hannah Cole, the marketing director of Creative Bioarray, “Except for GPCR screening service, “Creative Bioarray also provides a series of analytical services and solutions for epigenetic therapy research, kinase screening services, transporter screening services, as well as HSP90 screening services in order to accelerate modern drug discovery processes.”

About DDA platform
As a mature division of Creative Bioarray, DDA platform definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.

Contact Info:
Name: Hannah Cole
Email: Send Email
Organization: Creative Bioarray
Address: New York 11967, USA
Phone: 1 631 386 8241

Source URL:

Source: MarketersMedia

Release ID: 88994083

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.